| Image Class: | skin-invert-image |
| Width: | 200px |
| Class: | Serotonin receptor modulator
|
| Atc Prefix: | None |
| Pubchem: | 121008224 |
| Chemspiderid: | 63001243 |
| Synonyms: | 4-Hydroxy-N-ethyltryptamine |
| Iupac Name: | 3-[2-(ethylamino)ethyl]-1H-indol-4-ol |
| C: | 12 |
| H: | 16 |
| N: | 2 |
| O: | 1 |
| Smiles: | CCNCCC1=CNC2=C1C(=CC=C2)O |
| Stdinchi: | 1S/C12H16N2O/c1-2-13-7-6-9-8-14-10-4-3-5-11(15)12(9)10/h3-5,8,13-15H,2,6-7H2,1H3 |
| Stdinchikey: | AGYHPYWJOGSFII-UHFFFAOYSA-N |
4-HO-NET, also known as 4-hydroxy-N-ethyltryptamine, is a serotonin receptor modulator and putative psychedelic drug of the tryptamine and 4-hydroxytryptamine families related to norpsilocin (4-HO-NMT).[1] It was not included by Alexander Shulgin in his 1997 book TiHKAL (Tryptamines I Have Known and Loved) and its properties and effects in humans are unknown. The drug acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor. It produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, albeit with about 13-fold lower potency than psilocin (4-HO-DMT). Unlike 4-HO-NET, norpsilocin is notably inactive in this test. In addition to its psychedelic-like effects, 4-HO-NET produces hypolocomotion and hypothermia in rodents. 4-HO-NET was first described in the scientific literature by Alexander Sherwood and colleagues by 2024.
